Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nemiralisib dose-response study in acute COPD exacerbation
2017-001074-42Phase 2Terminated
- Sponsor
- GSK
- Start
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nemiralisib in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Started Aug 2017; status: terminated.
02
Drugs
nemiralisib
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2017-001074-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001074-42.